US Patent # RE38,604. Fluid therapy with L-lactate and/or pyruvate anions

United States Patent	RE38,604
Veech	September 28, 2004

Fluid therapy with L-lactate and/or pyruvate anions

Abstract

Electrolyte solutions are provided which are useful in electrolyte and fluid therapy, parenteral nutrition and dialysis. The Na:Cl ratio is normalized, plasma and cellular pH are normalized and cellular cofactor ratios are normalized in a manner which decreases toxicity over prior art solutions.

Inventors:	Veech; Richard L. (Rockville, MD)
Assignee:	BTG International Limited (London, GB)
Appl. No.:	10/060,169
Filed:	February 1, 2002

Related U.S. Patent Documents


	Application Number	Filing Date	Patent Number	Issue Date
	846081	Mar., 1992
	940333	Dec., 1986	5100677
	810918	Dec., 1985
	748232	Jun., 1985	4663166
	623102	Jun., 1984
Reissue of:	179880	Jan., 1994	06020007	Feb., 2000

Current U.S. Class:	424/677 ; 424/678; 424/679; 424/680; 424/681; 424/719; 514/529; 514/546; 514/557; 514/561; 514/572
Current International Class:	A61K 33/10 (20060101); A61K 33/06 (20060101); A61K 33/14 (20060101); A61K 31/19 (20060101); A61M 1/16 (20060101); A61M 1/28 (20060101); A61K 31/185 (20060101); C12N 5/00 (20060101); A61K 033/14 (); A61K 033/02 (); A61K 031/215 (); A61K 031/22 ()
Field of Search:	424/677,678,679,680,681,719 514/529,546,557,561,572

References Cited

U.S. Patent Documents


4067999	January 1978	Glabe et al.
4351835	September 1982	Stanko
4363815	December 1982	Yu et al.
4579955	April 1986	Lammerant et al.
4663166	May 1987	Veech
4771074	September 1988	Lammerant et al.
5100677	March 1992	Veech
5292774	March 1994	Hiraide et al.

Foreign Patent Documents


0108820	May., 1984	EP
0161472	Nov., 1985	EP
WO 86/00227	Jan., 1986	WO
WO 86/00228	Jan., 1986	WO
WO 86/00239	Jan., 1986	WO
WO 86/00335	Jan., 1986	WO

Other References

PL. Kirkendol et al., vol. XXIII Trans. Am. Soc. Artif. Intern. Organs (1977) pp. 399-405. .
Martindales Extra Pharmacopoeia, 28.sup.th edition (1982) pp. 634, 637, 638, 640 and 641. .
The Journal of Biological Chemistry, vol. 259, No. 1, pp. 231-236, Jan. 10, 1984, The Metabolism of Acetone in Rat, Casazza, et al. .
The New England Journal of Medicine, vol. 306, No. 22, pp. 1344-1348, Jun. 3, 1982, D-Lactic Acidosis Due to Abnormal Gut Flora, Stolberg, et al. .
The New England Journal of Medicine, vol. 301, No. 5, pp. 249-251, Aug. 2, 1979, D-Lactic Acidosis in a Man With the Short-Bowel Syndrome, Oh, et al. .
The Journal of Pediatrics, vol. 102, No. 2, pp. 234-238, Feb. 1983, D-Lactic Acidosis in Children: An Unusual Metabolic Complication of Small Bowel Resection, Perlmutter, et al. .
Fresenius-Infusionstherapie (1983) S. 211. .
DAB S 712 713 Anlage III + Rostffzert (1968). .
Jap. J. Artificial Organs 12 (1983) S 878-882. .
Kirkendol et al.--Chem. Abst. vol. 88 (1978) p. 479e. .
Gerlach--Chem. Abst. vol. 101 (1984) p. 43636h. .
Nagy et al.--Chem. Abst. vol. 78 (1973) p. 47685c. .
The Merck Index--Ninth edit. (1976), pp. 364 & 1041. .
Latta, T. (1832) Malignant Cholera, Documents . . . Relative to the Treatment of Cholera by Copious Injection of Aqueous & Saline Fluids Into The veins, Lancet ii; 272-277. .
Ringer, S. (1883) A Further Contribution Regarding the Influence of the Different Constituents of the Blood on the Contraction of the Heart, J. Physiol. 4: 29-42. .
Hartman, A. F. (1934) Theory & Practice of Parenteral Fluid Administration, JAMA 103: 1349-1354. .
Locke, F. S. (1900) Die Wirkung der Metalle des Blutplasma & Verschiedener Zucker auf das Isolirte Saugerthierherz, Zentrablatt fuer Physiologie 14: 670-673. .
Krebs, H. A., Henseleit, K. (1932) Untersuchugen uber die Harnstoffbildung im iterkorper. Hoppe-Seyler's Z Physiol. Chem. 210-33-66. .
Krebs, H. A. (1950) Body Size & Tissue Respiration, Biochem. Biophys. Acta 4: 249-269. .
Fox, C. H., Winfield, J. M., Slobody, L. B., Swindler, C. M., Lattimer, J. K. (1952) Electrolyte Solution Approximating Plasma Concentrations with Increased. .
Potassium for Routine Fluid & Electrolyte Replacement, JAMA 148 827-833. (no publication date available). .
Mion, C. M., Hegstrom, R. M., Boen, S. T., Scribner, B. H. (1964) Substitution of Sodium Acetate for Sodium Bicarbonate in the Bath for Hemodialysis Trans. .
Documenta Geigy Scientific Tables (1962 Essellier, A. F., Jeanneret, P. Aqueous Solutions--Parenteral Infusion Therapy. pp. 331-334 Geigy Pharmaceutical Co. Ltd., Manchester. .
Veech, R. L., Eggleston, L. V., Krebs, H. A. (1969) The Redox State of Free Nicotin Amide-Adenine Dinucleotide Phosphate in the Cytoplasm of Rat Liver Biochem. J., 115 609-619. .
Veech, R. L., Lawson, J. W. R., Cornell, N. W., Krebs, H. S. (1979) Cytosolic Phosphorylation Potential J. Biol. Chem., 254: 6538-6547. .
Veech, R. L., Cook, G. A., King, M. T. (1980) Relationship of Free Cytoplasmic Pyrophosphate to Liver Glucose Content & Total Pryophosphate to Cytoplasmic Phosphorylation Potential, FEBS Lett., 117: K65-K72. .
Sistare, F. D., Haynes Jr., R. C. (1985) The Interaction Between the Cytosolic Pyridine Mucleotide Redox Potential & Gluconeogenisis from Lactate/Pyruvate in Isolated Rat Hepatocytes. J. Biol. Chem., 260, 12748-12753. .
Sistare, F. D. Haynes Jr., R. C. (1985) Acute Stimulation by Gluconeogenisis from Lactate/Pyruvate in Isolated Hepatocytes from Normal and Adrenolectonized Rats, J. Biol. Chem., 260: 1254-12760. .
Tanford, C. S. (1950) J. Am. Chem. Soc., 72: 441-451, Preparation & Properties of Serum Plasma Proteins, XXIII, Hydrogen Ion Equilibria in Nature & Modified Human Serum Albumin. .
Pawn, G.L.S., Semple, S.J.G., Effect of 3-Hydroxybutyrate in Obese Subjects on Very-Low-Energy Diets and During Therapeutic Starvation, The Lancet, Jan. 1/8, 1983, pp. 15-17. .
Hejkek et al; Chemical Abstracts; vol. 90 (1979) p. 109, 863t. .
Chemical Abstracts; 11.sup.th collective; Chemical Substances Index (1982-1986), vol. 96-105, pp. 22327 cs, 22328cs and 54520cs. .
File wrapper of U.S. Pat. No. 5,292,744.to Hiraide et al. (no date applicable)..

Primary Examiner: Henley, II; Raymond
Attorney, Agent or Firm: Nixon & Vanderhye

Parent Case Text

RELATED APPLICATION

This is a continuation of application Ser. No. 07/846,081, filed Mar. 5, 1992 now abandoned which is a division of Ser. No. 06/940,333 filed Dec. 17, 1986, now U.S. Pat. No. 5,100,677 which is a continuation-in-part of my U.S. patent application Ser. No. 06/810,918, filed Dec. 18, 1985, now abandoned which in turn is a continuation-in-part of my U.S. patent application Ser. No. 06/748,232, filed Jun. 24, 1985, now U.S. Pat. No. 4,663,166, which in turn is a continuation-in-part of U.S. patent application Ser. No. 06/623,102 filed Jun. 22, 1984, now abandoned.

Claims

I claim:

1. A solution for rehydration, electrolyte replacement, and nutrition comprising water having dissolved therein the following components in the respective quantities indicated:

provided that in any given said solution, the pyruvate.sup.-, .[.d-beta-.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate.sup.- and acetoacetate.sup.- are the only monoanionic organic metabolic anions present, the solution does not contain .[.d-beta-.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate.sup.- and acetoacetate.sup.- anions in a ratio of 6:1 to 0.5:1 and the total amount of pyruvate.sup.-, .[.d-beta-.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate.sup.- and acetoacetate.sup.- anions present ranges from about 0.1 to 55 mM with the total amount of said cations being such as to achieve electrical neutrality in any given said solution, and further provided that said solution has a pH ranging from about 6.0 to 7.5.

2. A solution as defined in claim 1 wherein the solution further contains dissolved carbon dioxide.

3. A solution as defined in claim 1 wherein the solution further contains both bicarbonate anion and dissolved carbon dioxide.

4. A solution for dialysis therapy comprising water having dissolved therein the following components in the respective quantities indicated:

provided that in any given said solution, the pyruvate.sup.-, .[.d-beta-.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate.sup.- and acetoacetate.sup.- are the only monoanionic organic metabolic anions present, the solution does not contain .[.d-beta-.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate.sup.- and acetoacetate.sup.- anions in a ratio of 6:1 to 0.5:1 and the total amount of, pyruvate.sup.-, .[.d-beta-.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate.sup.- and acetoacetate.sup.- anions present in any given solution ranges from about 0.1 to 55 mM with the total amount of indicated cations present being such as to achieve electrical neutrality, and also provided that said solution has a pH ranging from about 5.0 to 8.2.

5. The solution of claim 4 wherein said solution additionally contains from about 20 to 55 mM of bicarbonate anions and wherein said solution also contains a sufficient portion of at least one of said pyruvate.sup.-, .[.d-beta-.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate.sup.- and acetoacetate.sup.- anions which are derived at least in part from the addition to said solution of, respectively, at least one of pyruvic acid, .[.d-beta-.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyric acid and/or acetoacetic acid in a total amount which is sufficient to produce pH in the range from about 5 to 8.2, and said solution contains sufficient nonionic dissolved nutrients to achieve a milliosmolarity of from about 250 to 550 mOsmole/Liter.

6. The solution of claim 4 wherein said solution additionally contains from about 20 to 55 mM of bicarbonate anions and wherein said solution also contains a sufficient portion of at least one of said pyruvate.sup.-, .[.d-beta-.]. .Iadd.D-.beta.-.Iaddend.hydroxy-butyrate.sup.- and acetoacetate.sup.- anions derived from the addition to said solution of, respectively, at least one of pyruvic acid, .[.d-beta-.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyric acid and/or acetoacetic acid in a total amount which is sufficient to produce pH in the range of from about 5.5 to 7.5, and said solution also contains sufficient nonionic dissolved nutrients to achieve a solution milliosmolarity of from about 260 to 550 mOsmoles/Liter.

7. A solution containing at least one anion species selected from the group consisting of pyruvate in an amount so that the concentration of pyruvate.sup.- anions in the fluid is in the range of about 0.01 to 40 millimole per liter, D-.beta.-hydroxybutyrate.sup.-, and acetoacetate.sup.-, and at least one cation selected from the group consisting of sodium.sup.+, potassium.sup.+, magnesium.sup.2+, calcium.sup.2+ and ammonium.sup.+, the total concentration of all said anions in said solution being in the range from about 0.01 to 2400 millimoles per liter wherein the solution further comprises one or more of (a) from about 20 to about 55 millimoles per liter of bicarbonate.sup.- anion, (b) from about 0.01 to about 2000 millimoles per liter of chloride.sup.- ion, (c) at least one nonionic dissolved nutrient in an amount sufficient to provide a solution osmolarity in said aqueous solution of from about 250 to about 550 milliosmoles per liter and (d) dissolved carbon dioxide and provided that the solution does not contain .[.D-p-.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate.sup.- and acetoacetate.sup.- anions in a ratio of 6:1 to 0.5:1.

8. A solution as defined in claim 7 wherein the solution further contains dissolved carbon dioxide.

9. A solution as defined in claim 7, wherein the solution further contains both bicarbonate anion and dissolved carbon dioxide.

10. A solution of claim 7 wherein the Ph is the range of 5 to 8.2.

11. A solution of claim 7 additionally containing chlorine anion in the range of 0.01 to 2000 millimoles per liter.

12. A solution of claim 7 additionally containing glucose in the range of 0.01 to 540 millimoles per liter.

13. A solution for enteral or parenteral administration to a patient comprising: an electrically neutral aqueous solution of at least one cation and at least one anion, wherein the sole monoanionic organic metabolic anion present in said aqueous solution is pyruvate anion, present in an amount of from about 0.1 to about 40 millimoles per liter of said aqueous solution, said aqueous solution containing substantially no D-lactate or acetate anions, and said aqueous solution having a pH of from about 5 to about 8.2, wherein the solution further comprises one or more of (a) from about 20 to about 55 millimoles per liter of bicarbonate anion, (b) from about 0.01 to about 2000 millimoles per liter of chloride ion, and (c) at least one nonionic dissolved nutrient in an amount sufficient to provide a solution osmolarity in said aqueous solution of from about 250 to about 550 milliosmoles per liter.

14. A solution as defined in claim 13, further comprising from about 20 to about 55 millimoles per liter of bicarbonate anion.

15. A solution as defined in claim 13, further comprising from about 0.01 to about 2000 millimoles per liter of chloride ion.

16. A solution as defined in claim 13, further comprising at least one nonionic dissolved nutrient in an amount sufficient to provide a solution osmolarity in said aqueous solution of from about 250 to about 550 milliosmoles per liter.

17. A solution as defined in claim 13, wherein said at least one cation is selected from the group consisting of sodium ions, potassium ions, calcium ions, magnesium ions, and mixtures of sodium ions with any of potassium ions, calcium ions and magnesium ions.

18. A solution for enteral or parenteral administration to a patient comprising: an electrically neutral aqueous solution of at least one cation and at least one anion, wherein the sole monoanionic organic metabolic anion present in said aqueous solution is D-.beta.-hydroxybutyrate anion, present in an amount of from about .[.0.1 to about 55.]. .Iadd.0.01 to about 2400 .Iaddend.millimoles per liter of said aqueous solution, said aqueous solution containing substantially no D-lactate or acetate anions, and said aqueous solution having a pH of from about 5 to about 8.2, wherein the solution further comprises one or more of (a) from about 20 to about 55 millimoles per liter of bicarbonate anion, .Iadd.and .Iaddend. .[.(b) from about 0.01 to about 2000 millimoles per liter of chloride ion, and.]. .[.(c).]. .Iadd.(b) .Iaddend.at least one nonionic dissolved nutrient in an amount sufficient to provide a solution osmolarity in said aqueous solution of from about 250 to about 550 milliosmoles per liter.

19. A solution as defined in claim 18, further comprising from about 20 to about 55 millimoles per liter of bicarbonate anion.

20. A solution as defined in claim 18, further comprising from about 0.01 to about 2000 millimoles per liter of chloride ion.

21. A solution as defined in claim 18, further comprising at least one nonionic dissolved nutrient in an amount sufficient to provide a solution osmolarity in said aqueous solution of from about 250 to about 550 milliosmoles per liter.

22. A solution as defined in claim 18, wherein said at least one cation is selected from the group consisting of sodium ions, potassium ions, calcium ions, magnesium ions, and mixtures of sodium ions with any of potassium ions, calcium ions and magnesium ions.

23. A solution for enteral or parenteral administration to a patient comprising: an electrically neutral aqueous solution of at least one cation and at least one anion, wherein the sole monoanionic organic metabolic anion present in said aqueous solution is acetoacetate anion, present in an amount of from about 0.1 to about 55 millimoles per liter of said aqueous solution, said aqueous solution containing substantially no D-lactate or acetate anions, and said aqueous solution having a pH of from about 5 to about 8.2, wherein the solution further comprises one or more of (a) from about 20 to about 55 millimoles per liter of bicarbonate anion, (b) from about 0.01 to about 2000 millimoles per liter of chloride ion, and (c) at least one nonionic dissolved nutrient in an amount sufficient to provide a solution osmolarity in said aqueous solution of from about 250 to about 550 milliosmoles per liter.

24. A solution as defined in claim 23, further comprising from about 20 to about 55 millimoles per liter of bicarbonate anion.

25. A solution as defined in claim 23, further comprising from about 0.01 to about 2000 millimoles per liter of chloride ion.

26. A solution as defined in claim 23, further comprising at least one nonionic dissolved nutrient in an amount sufficient to provide a solution osmolarity in said aqueous solution of from about 250 to about 550 milliosmoles per liter.

27. A solution as defined in claim 23, wherein said at least one cation is selected from the group consisting of sodium ions, potassium ions, calcium ions, magnesium ions, and mixtures of sodium ions with any of potassium ions, calcium ions and magnesium ions.

28. A solution for rehydration, electrolyte replacement, and nutrition comprising water having dissolved therein the following components in the respective quantities indicated:

and as a sole monoanionic organic metabolic anion present in said solution, a monoanionic organic metabolic anion selected from the group consisting of pyruvate, D-.beta.-hydroxybutyrate and acetoacetate, said organic metabolic anion being present in an amount of from about 0.1 to about 55 millimoles per liter of solution, except for pyruvate which may be present in an amount of from about 0.1 to about 40 millimoles per liter of said solution, said solution containing substantially no D-lactate or acetate anions, the total amount of said cations present in said solution being sufficient to provide electrical neutrality and said solution having a pH of from about 6.0 to about 7.5.

29. A solution for dialysis therapy comprising water having dissolved therein the following components in the respective quantities indicated:

and as a sole monoanionic organic metabolic anion present in said solution, a monoanionic organic metabolic anion selected from the group consisting of pyruvate, D-.beta.-hydroxybutyrate and acetoacetate, said organic metabolic anion being present in an amount of from about 0.1 to about 55 millimoles per liter of solution, except for pyruvate which may be present in an amount of from about 0.1 to about 40 millimoles per liter of said solution, said solution containing substantially no D-lactate or acetate anions, the total amount of said cations present in said solution being sufficient to provide electrical neutrality and said solution having a pH of from about 5 to about 8.2.

30. A solution for rehydration, electrolyte replacement, and nutrition comprising water having dissolved therein the following components in the respective quantities indicated:

wherein the solution further comprises one or more of (a) from about 20 to about 55 millimoles per liter of bicarbonate.sup.- anion, (b) from about 0.01 to about 2000 millimoles per liter of chloride.sup.- ion, (c) at least one nonionic dissolved nutrient in an amount sufficient to provide a solution osmolarity in said aqueous solution of from about 250 to about 550 milliosmoles per liter and; (d) dissolved carbon dioxide.

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention lies in the field of fluid therapy in humans, and more particularly in the field of aqueous solutions for parenteral, oral, dialysis, and irrigation therapy which employ at least one of l-lactate anions, pyruvate anions, d-betahydroxybutyrate anions, acetoacetate anions, or mixtures thereof in combination with selected cations.

2. Prior Art

Previously, I have provided improved electrolyte solutions for in vivo and in vitro usage which contain l-lactate and pyruvate anions, and/or d-betahydroxybutyrate and acetoacetate anions in respective defined ratios in combination with defined Na:Cl ratios; see my copending U.S. patent applications Ser. Nos. 748,232 and 747,792, both filed Jun. 24, 1985, and also my copending U.S. patent application Ser. Nos. 747,858 and 748,184, also filed on such date. However, it is now appreciated that the benefits of using l-lactate, pyruvate, d-betahydroxybutyrate, and/or acetoacetate anions need not be restricted by these previously taught relationships of anion pair ratios to Na:Cl ratios.

The prior art indicated in the "Background" sections of these earlier patent applications is incorporated by reference into the present application.

Previously, only racemic mixtures of lactate anions containing both d- and l-forms of lactate have been used in aqueous solutions for human parenteral therapy. The other major organic anion used in human parenteral fluids has been acetate. So far as is now known, the natural l-form of lactate anion has heretofore never been used, apart from the unnatural d-form, in human fluid therapy.

Sodium lactate solutions, used in pharmaceutical practices, are not specified in terms of isomeric structure. In the U.S. and British Pharmacopeias, lactate is defined and approval was duly granted for use of the d,l-lactate mixture. Hence, the d,l-lactate is the form used in contemporary pharmaceutical practice. The l-lactate is recognized to be the physiologically predominant form which is metabolized by different pathways and with different effects than is the d-lactate.

The toxicity of d-lactate has been described in humans (see Oh M S et al N Eng J Med 301: 249-251, 1979; Perlmutter, D H et al J Pediatrics 102: 234-238, 1983; Stolberg, L et al N Eng J Med 306: 1344-1348, 1982). Thus, the d-form has now been discovered to cause adverse and toxic effects when administered to mammals. For example, when an aqueous 20 mM/l d-lactate (or d-lactic acid) is administered parenterally to a rat, swelling of brain tissue is observed because the brain takes in the slowly metabolized d-lactate.sup.- plus an equivalent amount of K.sup.+. With continued administration, coma develops, the cerebral edema worsens and death ensues. In contrast, when l-lactate is similarly administered, the differential concentration of l-lactate between intracellular and extracellular fluid does not cause coma or death. For another example, Veech et al. (Veech, R L and Fowler, R C., "Cerebral Dysfunction and Respiratory Alkalosis During Peritoneal Dialysis with d-Lactate Containing Peritoneal Dialysis Fluids", Am. J. Med., 1987 (in press)) points out that the severe recurrent metabolic alkelemia described by Kenamond et al. ("Severe Recurrent Alkalemia in a Patient Undergoing Continuous Cyclic Peritoneal Dialysis", Am. J. Med., 548-550, 1986) was secondary to an encephalopathy caused by the inclusion of d,l-lactate in routine dialysis fluids. Because of such encephalopathological results, parenteral solutions containing the racemic d,l-lactate anions should not be administered for therapeutic purposes.

All previous commercial formulations of fluids for human therapy use lactate or lactic acid in the racemic d,l form as defined in the United States or British Pharmacopeia (see the United States Pharmacopeia 21st edition, January 1985, p 581, 945-946, 1186; United States Pharmacopeia Convention, Rockville, and British Pharmacopeia 1980, p 250, 666, 667, Her Majesty's Stationary Office, London). Sodium d,l-lactate solutions are currently and conventionally used for three major purposes in current medical practice. First, sodium d,l-lactate solution is used parenterally as an alkalinizing agent to correct acidosis. Secondly, it is used in parenteral fluid therapy to normalize the Na:Cl ratio from the 1:1 ratio found in normal saline. Thirdly, it is used as the counter ion in peritoneal dialysis solutions. In addition, it could also be used in current hemodialysis to replace the acetate anion, or, in its H.sup.+ form, as an acid to be added to a bicarbonate hemodialysis fluid.

Prior to the teachings contained in my afore referenced U.S. Ser. No. 748,232, pyruvate anions d-betahydroxybutyrate anions, and acetoacetate anions in aqueous solution, so far as is now known, were never used in human therapeutic fluids.

BRIEF SUMMARY OF THE INVENTION

This invention relates to a process for accomplishing fluid therapy without encephalopathy or metabolic bone disease and other complications resulting from use of present fluid formulations in a living human involving the introduction into the body of such human an aqueous solution containing at least one permeant monoanionic metabolite selected from the group consisting of l-lactate anions, pyruvate anions, .[.d-betahydroxybutyrate.]. .Iadd.D-.beta.-hydroxybutyrate .Iaddend.anions, acetoacetate anions, or mixtures of such anions.

Here, l-lactate is defined as that form of lactate anion found in mammalian tissues and designated l or L-lactate. It is identified by its ability to react with NAD.sup.+ to form pyruvate in a reaction catalyzed by mammalian lactate dehydrogenase (EC 1.1.1.27). The form of l-lactate which is dextrorotatory in aqueous solution is designated l-(+) while the salts of l-lactate which in aqueous solution are levorotatory are designated l-(-)lactate (see US Dispensatory, Osol, A, Pratt, R, Gennar, A R, eds. p 658. J R Lippcott. Philadelphia, 1973). Pyruvate and acetoacetate have no sterospecificity.

More particularly, this invention is directed to improved methods and optionally stable fluids for conventional administration to humans such as, (a) oral ingestion of an aqueous solution containing at least one of such anions, or a mixture of such anions, (b) parenteral therapy involving, for example, the intravenous administration of an aqueous solution containing at least one of such anions, or a mixture thereof, (c) dialysis therapy (hemo or peritoneal) using aqueous solutions containing at least one of such anions, (d) dialysis therapy (hemo or peritoneal) where acetic acid is replaced with at least one acid of the group consisting of l-lactate, pyruvate, .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate or acetoacetic acid, preferably l-lactate, and/or (e) irrigation therapy.

One presently preferred such anion comprises l-lactate. Thus, surprisingly, encephalopathy, metabolic bone disease, and many other complications are not only completely avoided by using l-lactate (or one of the other metabolite anions herein identified and used in the practice of this invention) in place of racemic d-l-lactate, but also the substitution of, for example, l-lactate for d-l-lactate, in solutions employed in fluid therapy, does not cause any change in the heretofore known beneficial physiological or pharmacological effectiveness of such fluids.

In general, a solution containing at least one such anion is administerable for generally the same purposes that prior art parenteral fluids or dialysis fluids are used which contain racemic d-l-lactate anions. For examples, such a solution can be used to treat acidosis, dehydration, blood electrolyte depletion, shock, malnutrition, uremia and the like.

Because mixtures of l-lactate anions and pyruvate anions, and mixtures of .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate anions and acetoacetate anions, in solutions each constitute near-equilibrium couples, which can vary widely in concentration under normal physiological conditions, as explained, for example, in my aforereferenced U.S. patent application Ser. No. 748,232, these anions can be employed with little or no adverse side effects in parenteral fluids and the like. Moreover, the therapeutic use of these anion couples (a) tends to maintain a normal plasma milliequivalent ratio of sodium cations to chloride anions, (b) thus tends to prevent hyperchloremic acidosis, and (c) accomplishes electrolyte and fluid and resuscitation therapy. The anions taught by this invention permit one to avoid the known untoward effects of high levels of the d-lactate anion (see Veech, R L, Fowler, R C, op. cited above) or of acetate anions which are now the major organic anions conventionally added to parenteral fluids (See Veech R L. The toxic impact of parenteral solutions on the metabolism of cells: a hypothesis for physiological parenteral therapy. Am J Clin Nutr 44: 519-551, 1986).

Other and further objects, aims, purposes, features, advantages, embodiments, applications, and the like will be apparent to those skilled in the art from the teachings of the present specification taken together with the claims.

DETAILED DESCRIPTION

For the fluid therapy purposes of my present invention, any conventional administration procedure is suitable, although parenteral (particularly intravenous) administration during hemo or peritoneal dialysis is presently preferred.

For example, sodium l-lactate aqueous solutions, which are stable and easily sterilized, can be used in infusion fluids in place of sodium bicarbonate for treatment for acidosis. For example, the bicarbonate may be dissolved immediately before use in the infusion fluid by light agitation and preferably warmed to body temperature. In such a replacement, 1 g sodium bicarbonate corresponds to about 1.33 g sodium l-lactate, and 1 g sodium l-lactate corresponds to about 0.75 g sodium bicarbonate. The bicarbonate or l-lactate solutions are preferrably administered diluted with glucose solution or distilled water. The alkalizing action of sodium l-lactate is diminished in severe liver damage since its breakdown is retarded. See, for example, Documenta Geigy 6th ed. pp. 331-332, Geigy, Manchester, 1962.

In practice, the calculation of the quantity of an alkalizing infusion solution required for adults is based on an average value for the water content of the body of 50% by weight and on a uniform intra- and extra-cellular distribution of bicarbonate, l-lactate, .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate, and other aforementioned permeant monovalent anionic metabolites. This method naturally yields only rough figures. The calculation can be simplified by reckoning in milliequivalents desired change in the alkali reserve. For example, in order to increase or decrease the alkali reserve in a patient weighing 70 kg by 5 mEq, a quantity of, for example, l-lactate, bicarbonate or .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate anions of 70.times.6.times.0.5=210 mEq must be administered. In order to avoid the danger of an acidosis becoming converted into an alkalosis, it is advisable not to attempt a complete normalization of the alkali reserve by means of an alkalizing solution, and such solutions should never be administered without supplementary potassium.

In children, a higher water content of about 66% must be reckoned with, so that the calculation yields relatively high infusion quantities. The differences between the calculated and observed effects of alkalizing and of acidifying compounds can be considerable since the above approximate calculation ignores a number of important factors.

In diabetic acidosis, many authors consider it is inadvisable to administer large quantities of sodium salts without potassium salts. On the other hand, extremely good results have been reported in the intensive lactate treatment of diabetic coma. There is no doubt that a moderate alkali therapy with l-lactate and/or pyruvate is indicated in diabetic ketosis with very much lowered alkali reserve, since it has been shown that insulin activity is inhibited by acidosis and that acidosis increases the blood sugar. Clearly use of .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate or acetoacetate would not be suitable for use in diabetic ketoacidosis. As those skilled in the art will also appreciate, the ketone bodies would not be appropriate for use in pregnant women.

When using solutions such as "Lactated Ringer's" (see, for example, my aforereferenced U.S. Ser. No. 748,232) to replete body water and electrolytes, the 28 mM d,l-lactate of the prior art is replaced with, for example, 28 mM l-lactate. In this way, the Na:Cl ratio, in such an l-lactate solution, is moved, if desired, towards a normal ratio of 1.36 as found in normal human plasma. Thus, hyperchloremic acidosis resulting from large infusions of normal sodium chloride solutions is avoided. The same considerations apply to use of such solutions in dialysis (see, for example, my aforereferenced U.S. patent applications Ser. Nos. 748,232 and 748,184).

Alternatively, in all the present new solutions, .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate anions, for example, can be used alternatively in place of l-lactate anions. Additional benefits may accrue from the use alternate or combined use of pyruvate and acetoacetate.

A preferred application for this invention involves usage of a mixture of anions of l-lactate and pyruvate, or a mixture of anions .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate and acetoacetate, as indicated, in solutions. Under special circumstances, use of one or the other of such anions alone may be preferred, such as in cases of severe reduction of the pyridine nucleotide systems where administration of pyruvate anions may be preferred. In conditions where long stability of mixed aqueous solutions presents a practical problem, use of l-lactate or .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate alone confers stability on the solution and is to be preferred over the currently used d,l-lactate or acetate.

For one example, to correct an acidosis wherein a 70 kg man is 6 mEq below the normal plasma bicarbonate level of 26-30 mEq/L, then 70.times.6.times.0.5 or 210 mEq is infused with a fluid of this invention containing bicarbonate anions and l-lactate anions as described hereinbelow, over a 2 to 4 hour period. Other dosages and rates of infusion may be used, if desired, depending on the clinical situation.

For a second example, a liter of solution of the composition of the current Ringer's lactate (for the composition thereof, see my aforereferenced U.S. Ser. No. 748,232) may be infused over a four hour period into a dehydrated 70 kg man with the exception that the d,l-lactate used is replaced with l-lactate.

For a third example, the prior art accomplishment of peritoneal dialysis by infusion into the peritoneum of 2 L of a conventional d,l-lactate based or acetate based peritoneal dialysis solution, is changed in that the 35-45 mM d,l-lactate or acetate is altered and replaced by 35-45 mM l-lactate. After remaining in the peritoneum for about 1/2 hour, the fluid is drained off and the process repeated until the blood urea nitrogen (BUN) is decreased to the level desired.

In parenteral therapy, the total concentration of anions selected from the above indicated anion group, a present preference being l-lactate, pyruvate, and/or mixtures thereof, can range from about 0.01 to 2400 millimoles per liter, though larger and smaller quantities can be used depending upon circumstances. The rate of introduction into a human patient, and the dosage used, are generally the same as are conventionally used in solutions containing, for example, d,l-lactate.

A present preference is to employ, for fluid therapy, an aqueous solution wherein the total concentration of l-lactate or pyruvate anions ranges from about 1 Molar to 1 millimolar. In a more preferred form, from about 28 to 45 millimoles (total) of such anions are present (such as in an improved Ringer's lactate or in improved peritoneal dialysis fluids).

Although a solution taught by the present invention may contain either l-lactate or pyruvate alone, as essentially the sole organic metabolic anion, a mixture of l-lactate anions and pyruvate anions may also be used, and similarly a mixture of .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate anions and acetoacetate anions may be used. When such an anion redox couple is employed, it is presently preferred to employ a milliequivalent ratio of l-lactate anions to pyruvate anions in the range from about 20:1 to 1:1, and a milliequivalent ratio of .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate anions to acetoacetate anions in the range from about 6:1 to 0.5:1.

The l-lactic, pyruvic, .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyric, and acetoacetic acids themselves as such, may be used. For example, such can be used in combination with aqueous bicarbonate anions; for instance, in sodium bicarbonate containing solutions. Also, one can employ, in the starting solutions used in the processes of present invention, aqueous solutions which contain, along with such metabolite anions as taught in this invention, at least one cation selected from the group consisting of sodium, potassium, calcium, magnesium, and ammonium. Preferably, from about 0.01 to 2400 millimoles per liter of such anions are present.

Inorganic physiologically acceptable anions, besides bicarbonate, may also be present, such as chloride, phosphate, and sulfate, if desired, and if such are present, the respective quantities present are preferably similar to corresponding physiologic levels. A difference between the total milliequivalents of the cations present in a solution and the total milliequivalents of the organic anions of the specified group employed in the practice of this invention (l-lactate, pyruvate, .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate, and acetoacetate) can be provided by other physiologically acceptable anions.

It is considered to be physiologically advantageous and it is generally preferred in the practice of this invention, to maintain the levels of the respective organic metabolite anions employed at values which are approximately physiologic. Also, when a mixture of the monocarboxylic metabolic anions is employed in a given solution, it is not necessary to employ redox couple anion pairs since this use of these defined monocarboxylic metabolite anions does not produce the toxic effects resulting from the present use of d,l-lactate or acetate. Further, it appears to be desirable to employ such anionic metabolites in combination with bicarbonate anions in conditions where large volumes of fluid are to be used and administration of calories is not desired, such as in peritoneal dialysis.

Additionally and preferably, such a solution may contain dissolved therein at least one osmotically active, substantially nonioinic substance in accord with, for example, teachings for prior art d,l-lactate and acetate containing solutions. Examples of suitable such nonionic substances include glucose (preferred), fructose, glycerol, sorbitol, and the like. Typically, and preferably, such a solution has an osmolarity ranging from about 240 to 2400 mOsmoles/liter.

In addition, formulations containing ionic nutrients, such as l-amino acids, can benefit from the addition of at least one of the metabolite monocarboxylic acid anions taught herein. For example, the acetate anions present in current commercial amino acid formulations (which lead to metabolic bone disease) can be replaced by such anions. See, for example, my copending U.S. patent application Ser. No. 810,916, filed Dec. 18, 1985, and its continuation-in-part application filed on even date herewith, all the teachings of which are entirely incorporated hereinto by reference.

Also preferably, a starting solution used in the practice of this invention has a pH in the range from about 5 to 9, although for the contemplated human usage, a most preferred pH is about 7.4.

Additional cations and anions may be present in a starting solution as taught, for example, in my aforereferenced U.S. Ser. No. 748,232.

Thus, and as indicated above, such a solution can additionally contain bicarbonate anions. The pH of the resulting solution is adjustable to a desired value, such as a preferred value in the range from about 6 to 8.4, by the addition of the hydrogen form of at least one acid selected from the group consisting of l-lactic, .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyric, acetoacetic, and pyruvic in an amount sufficient to give such desired value. For example, when an anion of an acid such as l-lactic acid, pyruvate acid, .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate acid, or acetoacetic acid is to be added to a bicarbonate containing starting solution, a desired pH of such solution for use in human hemodialysis, or the like, is given by following the formula: ##EQU1##

where:

HA is the concentration of carboxylic acid in moles/liter, pK.sub.a' =6.10 at 38.degree. C. (see Hastings, A B, et al., J. Biol. Chem. 79: 183-192, 1928).

In preferred applications of this sort, such as applications which can incorporate from about 28 to 40 mM/l HCO.sub.3.sup.-, about 2 to 9 mM/l l-lactic, pyruvic, .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyric acid and/or acetoacetic acid may generally be added. Such solutions are presently preferred for peritoneal or hemodialysis over existing fluids containing acetic acid or d,l-lactate because of the toxicity of the presently used acids.

Optionally, carbon dioxide may additionally be dissolved in such a solution, for example, in a range such as taught in my aforereferenced U.S. Ser. No. 748,232.

For purposes of practicing the present invention, only when both l-lactate and pyruvate anions are present in a milliequivalent ratio of from about 20:1 to 1:1, and/or both .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate and acetoacetate anions are present in a milliequivalent ratio of from about 6:1 to 0.5:1 are present in admixture in a starting solution, and only when both sodium cations and chloride anions are also present in such a starting solution, then the milliequivalent ratio of Na.sup.+ cation to Cl.sup.- anions is always preferably below 1.24 or above 1.6. Thus, the practice of the methods of this invention does not require, in any given starting solution, both members of a redox active, near-equilibrium monocarboxylic acid couple; either member can be used individually. Also, such practice does not require the use of a narrowly specified range of Na.sup.+ or Cl.sup.- milliequivalent ratios (when such inorganic ions are both present).

Thus, as taught herein, therapy (including correction of acidosis, dialysis and/or fluid, electrolyte or nutrient replacement, and the like) in accord with the present invention can be accomplished through the use of any one or more of various anions herein taught in a starting solution wherein the cations are selected from among hydrogen, sodium, potassium, calcium, magnesium, and ammonium.

However, in the practice of this invention, preferably only one monoanionic permeant metabolite (l-lactate, pyruvate, .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate, and acetoacetate) is present in a solution at any one time. Thus, improvement in existing parenteral fluids can be achieved by use of l-lactate alone rather than d,l-lactate as is currently used, for example, in ambulatory parential dialysis fluids. The use of l-lactate in conjunction with other inorganic anions, but in the absence of the unstable ketoacid pyruvate, results in a fluid which has as long a chemical stability as the currently used d,l-lactate, but avoids the toxic effects resulting from the inclusion of the unnatural d-isomer. Thus, for example, one class of solutions, which has characteristically long shelf life and stability, contains as anions only l-lactate anions and/or .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate anions and is termed herein Class I for convenience. This class is particularly useful where long term fluid storage is desirable. Another class of solutions, for example, contains as anions only pyruvate anions and/or acetoacetate anions and is termed herein Class II for convenience. Another class of solutions, for example, contains as anions only a mixture of l-lactate anions and pyruvate anions, or only a mixture of .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate anions and acetoacetate anions, which is useful when redox control is desired, and is termed herein Class III for convenience. Table I illustrates various embodiments of such exemplary classes.

TABLE 1 Range of Concentration in mMoles/Liter Item No. Component Class I Class II Class III 1 1-lactate or 0.01-2400 betahydroxy- butyrate 2 pyruvate or 0.01-2400 acetoacetate 3 1-lactate plus 0.01-2400 pyruvate and/or [d-beta] D-.beta.- hydroxy- butyrate and acetoacetate 4 (cations) 10.sup.-5 -10.sup.-9 10.sup.-5 -10.sup.-9 10.sup.-5 -10.sup.-9 (hydrogen) 0-2400 0-2400 0-2400 sodium 0-2400 0-2400 0-2400 potassium 0-1200 0-1200 0-1200 calcium 0-1200 0-1200 0-1200 magnesium 0-1200 0-1200 0-1200 ammonium 0-10 0-10 0-10

Table II describes four classes of physiologic permeant monoanionic metabolite solutions suitable for each of three major fields of application. The genus class is described in Type A solutions of Table II, where d,l-lactate was previously used, and such improved solutions are suitable for use in treatment of certain forms of metabolic acidosis. For oral or parenteral use in resuscitation or the treatment of acidosis or severe fluid loss in diarrhea, the milliosmolarity of the solutions can vary widely from about 240 mOsmoles/L to 4800 mOsmoles/L. Prior art hypertonic sodium chloride solutions or hypertonic Ringer's lactate solutions have been widely used in resuscitation; such solutions can be reformulated as Type A solutions of this invention. Type B solutions of Table II are suitable for rehydration, electrolyte replacement, and/or nutrition. Type C solutions of Table II, are suitable for use as peritoneal dialysis and hemodialysis fluids. Type D solutions can be regarded as being similar in use to Type C solutions, but such include the permeant monoanionic metabolites in their hydrogen form in solutions which contain bicarbonate so as to achieve a desired pH in a manner which avoids the current toxic effects of high levels of acetate or d,l-lactate. These class D solutions are particularly suitable for use where it is desirable to avoid high levels of monocarboxylic acids. By using normal metabolites, these new fluids improve the corresponding prior art fluids, such as Ringer's lactate, hemodialysis fluids, and the like. With appropriate dosage, these fluids are also suitable for oral ingestion, such as under conditions requiring therapy where close patient monitoring is not possible.

For example, one can accomplish treatment of metabolic acidosis or resuscitation with improved sodium l-lactate or other Type A solutions as described in Table II. For treatment of acidosis, initial parenteral administration followed by oral administration is often preferred.

For example, one can accomplish parenteral fluid therapy with improved l-lactated Ringer's-type solutions (Type B) using the present invention in a human patient suffering from fluid, electrolyte, and/or nutritional depletion. Such a fluid may optionally contain non-ionic dissolved nutrients, usually glucose, from 0 to 280 mmoles/liter.

For another example, one can accomplish dialysis fluid therapy with an improved dialysis solution (Type C) using the present invention in a living human patient. The conventional techniques of hemo- and peritoneal dialysis known to the prior art are employable with the improved fluids of this type. Thus, the renal function of a living human patient is replaced at least in part by passing the blood of the patient over one face of a dialysis membrane while a dialysis fluid is passed over the opposite face of such membrane.

In hemodialysis, it is preferable to use a dialysis solution of Type D containing from about 20 to 55 mM/l of bicarbonate anions, such solution also contains a sufficient portion of anions of at least one of said l-lactate, pyruvate, .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyrate, and/or acetoacetate anions which are derived from the addition to said solution of, respectively, at least one of l-lactic acid, pyruvic acid, .[.d-beta.]. .Iadd.D-.beta.-.Iaddend.hydroxybutyric acid and/or acetoacetic acid in a total amount which is sufficient to produce a pH in the range from about 5.5 to 8.2, such solution also has a milliosmolarity of from about 250 to 310 mOs/l.

Similarly, when peritoneal dialysis is being practiced, a Type D solution containing bicarbonate can be used and the carboxylic metabolite acid material(s) as above described is/are (as the case may be) also present, but here in an amount sufficient to produce a pH ranging from about 5.5 to 7.5. The milliosmolarity ranges from about 280 to 550 mOs/l achieved by dissolution in such solution of sufficient nonionic nutrients.

Type D solutions are also adapted for parenteral administration, and for such purposes, a suitable composition of Type D is similar to that above indicated for peritoneal dialysis.

It will be appreciated that the designation mM and mM/l are used herein in their conventional manner to designate millimoles per liter.

TABLE II Preferred Solutions (New) units in mMoles/Liter solution Component Type A.sup.(1) Type B.sup.(2) Type C.sup.(3) Type D.sup.(4) Cations Na.sup.+ 0-2400 130-160 130-145 130-145 K.sup.+ 0-60 2-10 0-4 0-4 Ca.sup.2+ 0-4 0.5-2.5 0.5-2.0 0-2 Mg.sup.2+ 0-3 0-1.5 0-1.0 0-1 Anions Cl.sup.- 0-2000 90-115 90-120 95-110 HCO.sub.3.sup.- 0-2000 0 0-40 20-55 Pi.sup.-L8 0-50 0 0 SO.sub.4.sup.2- 0-1.2 0 d-lactate.sup.- 0 0 0 acetate.sup.- 0 0 0 l-lactate.sup.- 0-2400 0-55 0-55 0-20 pyruvate.sup.- 0-2400 0-55 0-55 0-20 [d-beta] D-.beta.- 0-2400 0-55 0-55 0-20 hydroxybutyrate.sup.- acetoacetate.sup.- 0-2400 0-55 0-55 0-20 Nonanionics Glucose 0-278 0-280 0-240 0-240 pH 5-8.2 6.0-7.5 5-8.2 5.5-8.2

EMBODIMENTS

The following examples are merely illustrative of the present invention and are not intended as a limitation upon the scope thereof.

EXAMPLES 1-4

The following Table III illustrates particular solutions of this invention:

TABLE III (Values are in mMoles/Liter) Ex. No. Component Class I Class II Class III 1 l-lactate.sup.(1) 1000 Na.sup.+ 1000 2 pyruvate.sup.(2) 1000 Na.sup.+ 1000 3 l-lactate.sup.(3) 900 pyruvate 100 Na.sup.+ 1000 4 l-lactic acid 5 Table III footnotes: .sup.(1) For treatment of acidosis see Merck Handbook p 1866 12th edition. .sup.(2) For treatment of acidosis when severe reduction of [NAD.sup.+ ]/[NADH] is present (see USSN 748,232). .sup.(3) For treatment of acidosis when redox balance is desired (see USSN 748,232). .sup.(4) For use as an additive to a bicarbonate containing solution (see USSN 748,232).

EXAMPLES 5-12

Illustrative examples of various physiological abnormalities which are treatable by using various starting solutions of the present invention are shown in Table IV below:

TABLE IV Exemplary Usenges Condition Where Useful Fluid Composition Route of and solution Cation(s) Anion(s) Administration, common name in mMoles/liter and Dose 5. Dehydration Na.sup.+ 130 Cl.sup.- 109 parenteral, (L-lactated K.sup.+ 3 l-lactate.sup.- 28 500 ml to 3 Ringers).sup.(1) Ca.sup.2+ 1.5 liters per day depending on severity and cause 6. Peritoneal Na.sup.+ 141 Cl.sup.- 101 Introperitoneal, Dialysis Ca.sup.2+ 1.75 l-lactate.sup.- 45 4 to 8, 2 liter (Dianeal.sup.(2) Mg.sup.2+ 0.75 bags per day w/1.5% (also dextrose 83) Dextrose, Travenol).sup.(3) 7. Metabolic Na.sup.+ 156.1 l-lactate 156.1 parenteral or Acidosis oral, 10 ml to (Isotonic 1 L depending sodium l- on size lactate of patient solution).sup.(4) 8. Cardiac Mg.sup.+ 145 Cl.sup.- 115 Intracoronary Reperfusion Ca.sup.2+ 0.5 HCO.sub.3.sup.- 25 infusion after Fluid.sup.(5) Na.sup.2+ 0.75 pyruvate.sup.- 11.5 cardiac arrest K.sup.+ 4 (also glucose 10 and CO.sub.2 1.2) 9. Dehydration Na+ 120.2 Cl.sup.- 104.7 parenteral or and Potassium K+ 36.2 l-lactate.sup.- 51.7 oral.sup.(8) Loss.sup.(6) in (may be diluted with Diarrhea, Keto- 2 volumes of 278 mMolar acidosis or glucose for pediatric Stress use) (Improved Darrow's Solution).sup.(7) 10. Hemo- Na.sup.+ 135 Cl.sup.- 106.5 Hemodialysis dialysis with K.sup.+ 2 HCO.sub.3.sup.- 33 without un- Bicarbonate Ca.sup.2+ 1.5 l-lactate physiolocal and l-lactic Mg.sup.2+ 0.375 acid 2 levels of acid.sup.(9) acetate.sup.(10) 11. Electrolyte Na.sup.+ 140 Cl.sup.- 103 Alternative to Replacement K.sup.+ 10 l-lactate 27.5 Fox's acetate HBDH- Ca.sup.2+ 2.5 [d-beta] 27.5 Ringer's Ringer's Mg 1.5 D-.beta.-hy- for electrolyte droxybutyrate replacement.sup.(11) Table IV Footnotes .sup.(1) Hartman A F. Theory and practice of parenteral fluid administration. JAMA 1934: 103: 1349-1354. .sup.(2) Dianeal is a trade mark of Travenol Laboratories, Deerfield Illinois .sup.(3) Facts and Comparisons. St. Louis: J B Lippincott, October 1981-August 1983: 35d-53. .sup.(4) Essellier A F, Jeanneret P. Aqueous solutions-parenteral infusion therapy. Documenta Geigy 6th edition. Manchester: Geigy, 1962: 324-334 .sup.(5) The period of reperfusion of heart following, for example coronary by pass can be critical and may result in permanent heart damage due to excessive calcium loading. Pyruvate is the preferred substrate for heart under these conditions giving maximal efficiency of cardiac work over either glucose plus l-lactate or glucose alone (See Kobayshi K, Neely J R. The control of maximum rates of glycolysis in rat cardiac muscle. Circ Res 1979: 55: 166-175. .sup.(6) Essellier A F, Jeanneret P. Aqueous solutions-parenteral infusion therapy. Documenta Geigy 6th edition. Manchester: Geigy, 1962: 332-333 .sup.(7) Darrow and Pratt. JAMA 1950: 143: 365-ff and 432-ff. .sup.(8) Martin et al. JAMA 1951, 147: 24-ff. .sup.(9) See Table XI, Prior Art Hemodialysis Fluids. WO 86/00227 .sup.(10) Blood acetate levels above the physiological level of 0.2 mM are associated with metabolic bone disease. Veech R L. Am J Clin Nutr 44: 544, 1986. .sup.(11) Fox C L. JAMA 1952: 148: 827-833.

It is to be understood that the invention is not limited to the features and embodiments hereinabove specifically set forth, but can be carried out in other ways and manners without departure from its spirit.

* * * * *